Metformin treatment may be associated with decreased levels of NT-proBNP in patients with type 2 diabetes |
| |
Authors: | M Rosiak M Postula A Kaplon-Cieslicka E Trzepla A Czlonkowski KJ Filipiak G Opolski |
| |
Affiliation: | 1. Department of Cardiology, Medical University of Warsaw, Warsaw, Poland;2. Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland;3. Medical Center, Medical University of Warsaw, Warsaw, Poland |
| |
Abstract: | PurposeIndividuals with type 2 diabetes (T2DM) are at increased risk of cardiovascular disease, including heart failure (HF). In patients with T2DM elevated serum concentrations of the N-terminal fragment of pro-B-type natriuretic peptide (NT-proBNP) correlate with cardiovascular morbidity and mortality. We aimed to identify predictors of increased serum NT-proBNP levels in patients with T2DM.MethodsThe study included 185 patients with T2DM treated with either oral antidiabetic agents (49.7%) or insulin (17.8%), or both (32.5%). We divided the patients into two groups: with high (>200 pg/mL) and low (≤200 pg/mL) NT-proBNP concentrations.ResultsWe found differences between the patients with high and low NT-proBNP levels including age, prevalence of dyslipidemia and HF, history of previous myocardial infarction (MI), heart rate, hemoglobin level, platelet count, creatinine, urea and uric acid concentrations, use of beta-blockers, loop diuretics, metformin and insulin. In a multivariate analysis metformin was a negative predictor of increased NT-proBNP concentration. Age, history of HF and decreased estimated glomerular filtration rate (eGFR) were positive predictors. We found no correlation between NT-proBNP serum concentration and insulin treatment or history of coronary artery disease or MI.ConclusionMetformin correlates with lower concentrations of NT-proBNP in patients with T2DM. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|